AGP Picks
View all

Falkland Islands Science Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Falkland Islands Science Times.

Press releases published on October 26, 2026

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
EarthDaily Awarded $3 Million NASA Task Order to Advance Commercial Earth Observation Integration with Landsat
Sixthfin Financial Close Automation Software 2026: Close Review and Control Layer Targets the Gap Between Completing the Close and Reviewing Its Output in UK Multi-ERP Enterprises
FasTreat Expands Virtual Mental Health Access in Canada, Reports More Than 28,000 Appointments
Initta Technology Showcases Smart Retail & Food Service Ecosystem in London
North Vector Dynamics Closes Series A Exceeding USD $20 Million, One of Canada’s Largest Defence Technology Financings
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekannt
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
CoinW Partners with EngageLab to Fortify Global Trading Communications
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
Phathom Pharmaceuticals Provides Update on FDA Litigation
Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Falkland Islands Science Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.